Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Kenvue

Kenvue Is Headed for a Merger Vote on January 29. How Should You Play KVUE Stock Here?

KVUE stock could gain 15% this week if the potential merger with Kimberly-Clark is approved by all major stakeholders.

Kenvue Stock: Analyst Estimates & Ratings

Kenvue Stock: Analyst Estimates & Ratings

As Kenvue has underperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Earnings Preview: What to Expect From Kenvue’s Report

Earnings Preview: What to Expect From Kenvue’s Report

Kenvue is gearing to release its fourth-quarter results shortly, and analysts expect its earnings to fall in low-double-digits.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks

Institutional insiders are placing big bets on DASH, KVUE, and KYMR. See how much is being spent on these three stocks and which investors are buying.

Kenvue Stock: Is KVUE Underperforming the Consumer Defensive Sector?

As Kenvue has performed weaker than the consumer defensive sector over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

3 Smart Defensive Stocks for an Uneasy Market

Recession risks persist despite record market highs. Here are three defensive stocks—including PG, JNJ, and the DIA ETF—that can help protect your portfolio

Court Rejects Bid To Block Kenvue's $398 Million Shareholder Payout In Tylenol Safety Dispute

On Friday, a Texas judge declined to halt an upcoming shareholder payout by Texas Attorney General Ken Paxton to restrict Kenvue Inc.'s (NYSE:KVUE) handling and marketing of Tylenol amid ongoing litigation over the product's safety for pregnant women.

inkl

Read news from The Economist, FT, and more,
with one subscription

Despite Trump’s claims, new review by experts finds no link between Tylenol use during pregnancy and autism

Despite Trump’s claims, new review by experts finds no link between Tylenol use during pregnancy and autism

Experts say pregnant women should still be advised to take Tylenol to treat pain and fever

The Independent UK

From Meta to PepsiCo: when does a company outgrow its biggest brand?

Is PepsiCo still just 'Pepsi' to most?

Judge denies Paxton request to block Tylenol maker from paying shareholders

Attorneys for Texas recognized their bid to block payments was an extraordinary request.

The Texas Tribune

Stocks Impacted by Trump’s Comments in 2025 — From Disney to Tesla

Stocks Impacted by Trump’s Comments in 2025 — From Disney to Tesla

Trump’s 2025 comments sent shockwaves through the market—see which major stocks, from Disney to Tesla, were impacted.

Sticker Shock: Why Kimberly-Clark's Sell-Off Is an Overreaction

Sticker Shock: Why Kimberly-Clark's Sell-Off Is an Overreaction

Kimberly-Clark's acquisition of Kenvue creates a global leader in health and wellness, positioning its iconic brands for accelerated long-term growth.

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark Snaps Up Tylenol Maker Kenvue in £30 Billion Takeover Amid Autism Controversy

Kimberly-Clark to acquire Kenvue, owner of Tylenol, in a £40 billion deal amid controversy over the painkiller's safety concerns and declining sales.

International Business Times UK

Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue

Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue

Consumer staples ETFs, usually the quiet corner of the market, are suddenly in the spotlight. The $48.7 billion acquisition of Kenvue Inc. (NYSE:KVUE) by Kimberly-Clark Corp (NASDAQ:KMB) has stirred renewed interest in the sector, setting up a potential reshuffling of weightings across several big-name ETFs.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Asian shares trade mixed after AI darlings prop up Wall Street

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology

Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today

On Monday, major U.S. indexes showed mixed performance — the Dow Jones Industrial Average slipped nearly 0.5% to 47,336.68, while the SP 500 edged up 0.2% to 6,851.97. The Nasdaq closed 0.46% higher at 23,834.72.

Stocks Close Higher on M&A and AI Optimism

The S&P 500 Index ($SPX ) (SPY ) on Monday rose +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) fell -0.52%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) rose +0.37%. December E-mini S&P futures (ESZ25 ) rose +0.09%, and December E-mini Nasdaq futures (NQZ25 ) rose...

International Business Times UK

Kimberly-Clark Confirms Kenvue Acquisition Deal: Why It Is Buying the Tylenol Maker

Kimberly-Clark's acquisition of Kenvue marks a major strategic shift as the company expands beyond its traditional personal care and diving deeper into the consumer health market.

Get all your
news in one place.

100’s of premium titles.
One news app.

Amazon Surge Sends S&P 500, Nasdaq Higher to Start November: Stock Market Today

Amazon inked a $38 billion cloud deal with OpenAI, which sent the stock to the top of the Dow Jones on Monday.

Options Corner: Kimberly-Clark's Implosion Offers An Unusual Informational Arbitrage Opportunity

Kimberly-Clark Corporation (NASDAQ:KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE:KVUE). Ordinarily, such an acquisition might make sense due to the implied expansion of the acquiring entity's product portfolio. However, Kenvue has been ground zero for a controversy involving the flagship over-the-counter…

Dear Kenvue Stock Fans, Mark Your Calendars for November 6 Upcoming earnings

Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Kenvue Stock Pops on News Kimberly-Clark Will Buy It for $48.7B. Is It Too Late to Buy KVUE Here?

Kenvue stock soars as Kimberly-Clark agrees to acquire the consumer health giant. Jim Cramer is positive on KVUE shares heading into 2026.

International Business Times UK

Kenvue Acquired by Kimberly-Clark in $48.7 Billion Deal to Form Consumer Staples Giant

Kimberly-Clark will acquire Kenvue in a $48.7 billion cash-and-stock deal, creating a new consumer health and personal care giant combining brands like Huggies, Kleenex, Johnson's Baby, and Band-Aid.

Stocks See Support From M&A and AI Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.08% the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.55%. December E-mini S&P futures (ESZ25 ) are up +0.16%, and December E-mini Nasdaq futures...

The Guardian - US

Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger

Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny

People

166,896 stories

Robert F. Kennedy Jr

Austan Goolsbee

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

the Supreme Court

The Independent

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

340,773 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play